Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

D. Dunbar Ivy, Aimee Doran, Lori Claussen, Deborah Bingaman, Anji Yetman

Research output: Contribution to journalArticle

70 Scopus citations

Abstract

In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.

Original languageEnglish (US)
Pages (from-to)943-946
Number of pages4
JournalAmerican Journal of Cardiology
Volume93
Issue number7
DOIs
StatePublished - Apr 1 2004

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan'. Together they form a unique fingerprint.

  • Cite this